MedPath

Sensitivity of Echography in Arthritis

Not Applicable
Conditions
Rheumatoid Arthritis
Registration Number
NCT00444691
Lead Sponsor
Association de Recherche Clinique en Rhumatologie
Brief Summary

It has been reported recently that the detection of synovitis by ultrasonography was more sensitive than clinical examination (Wakefield et al. Ann Rheum Dis).

An OMERACT and EULAR working party recently produced guidelines on the best way to record and score quantitatively synovitis of the small joints of the hands and feet (Wakefield R, D'Agostino MA).

It has also been presumed recently that ultrasonography was more sensitive to changes than clinical examination after anti-TNF treatment (Ref. Taylor et al). If this better sensitivity to change were to be confirmed, ultrasonography would be preferred to clinical examination in studies evaluating new treatments.

In everyday practice, better intrinsic validity of the evaluation of synovitis by ultrasonography would lead to widespread use of this technique in the diagnosis and treatment of rheumatoid arthritis patients.

Objective of this study is to compare the sensitivity to change in synovitis score according to the monitoring method used (clinical examination versus ultrasonography).

Detailed Description

This is a multicenter, (10 French centers and 1 Belgian center), prospective (4-month patients' follow-up) interventional study in 120 patients with rheumatoid arthritis justifying anti-TNF treatment.

The overall duration of the study will be 8 months composed of a 4-month inclusion period and a 4-month follow-up period for each patient. Moreover, X-ray evaluations of hands and feet will be performed 2 years from the beginning of the study in order to assess the changes in structural damage.

During the patients' participation, 6 visits are planned: an inclusion visit then, a follow-up visit at 1, 2 and 3 months from the inclusion visit, and a final evaluation visit at 4 months from the inclusion visit. At each visit, synovitis will be evaluated using both methods: clinical examination and ultrasonography. For a same patient, clinical evaluation of synovitis will have to be performed - during the entire study - by the same rheumatologist and the ultrasonographic evaluation will have to be performed by the same ultrasonographist (different from the rheumatologist) and always using the same ultrasonograph.

Finally, patients will be performed anterior X-rays of hands and feet two years from the beginning of the study whatever the ongoing RA treatment.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Patients with rheumatoid arthritis meeting ACR criteria.
  • Justifying anti-TNF alpha treatment (switch or first administration).
  • To have at least 6 synovitis at the clinical examination necessary for the DAS evaluation
  • To accept to participate in this study (informed consent signed).
Exclusion Criteria
  • Minor patients.
  • Pregnancy.
  • Breastfeeding.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
joint score evaluated by clinical examinationbaseline and 1, 2, 3 and 4 months after baseline
joint score evaluated by ultra-sonographybaseline and 1, 2, 3 and 4 months after baseline
Secondary Outcome Measures
NameTimeMethod
DAS28 Synovial indexbaseline and 1, 2, 3 and 4 months after baseline
ACR Synovial index (66 sites)baseline and 1, 2, 3 and 4 months after baseline

Trial Locations

Locations (10)

CHU-Brugmann

🇧🇪

Bruxelles, Belgium

Hôpital Ambroise Paré

🇫🇷

Boulogne, France

CHU de la Cavale Blanche

🇫🇷

Brest, France

CHU Côte de Nacre

🇫🇷

Caen, France

CHU A. Michallon

🇫🇷

Grenoble, France

Hôpital Bicêtre

🇫🇷

Le Kremlin Bicetre, France

Hôpital Cochin

🇫🇷

Paris, France

Hôpital de la Pitié

🇫🇷

Paris, France

CHU de RENNES - Hôpital Sud

🇫🇷

Rennes, France

CHU Nancy-Brabois

🇫🇷

Vandoeuvre Les Nancy, France

CHU-Brugmann
🇧🇪Bruxelles, Belgium

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.